Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance


Benzinga | Sep 24, 2020 07:33AM EDT

Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC